ENDORISK-2: A personalized Bayesian network for preoperative risk stratification in endometrial cancer, integrating molecular classification and preoperative myometrial invasion assessment
Incorporation of molecular data and preoperative MI improved the flexibility of ENDORISK with comparable diagnostic accuracy for estimating LNM as when based on low-cost immunohistochemical biomarkers. In addition, the high diagnostic accuracy in patients with low-grade EC demonstrates how ENDORISK-2 could aid clinicians in identifying patients in whom surgical lymph node assessment may safely be omitted. These results underline its power for clinical use in both high and low resource countries.
Authors
- Michiel Simons (ORCID: https://orcid.org/0000-0003-1039-3488)
- Peter Lucas (ORCID: https://orcid.org/0000-0001-5454-2428)
- Stephanie Vrede
- Jitka Hausnerová (ORCID: https://orcid.org/0000-0002-0522-1916)
- Frédéric Amant (ORCID: https://orcid.org/0000-0002-5452-4905)
- Nicole C.M. Visser (ORCID: https://orcid.org/0000-0003-3919-3922)
- Camilla Krakstad (ORCID: https://orcid.org/0000-0002-0174-8139)
- Antonio Gil‐Moreno (ORCID: https://orcid.org/0000-0003-1106-5590)
- Ingfrid S. Haldorsen (ORCID: https://orcid.org/0000-0001-9313-7564)
- Vít Weinberger (ORCID: https://orcid.org/0000-0003-4858-1951)
- Heidi V.N. Küsters‐Vandevelde (ORCID: https://orcid.org/0000-0002-1012-941X)
- Gemma Mancebo (ORCID: https://orcid.org/0000-0001-5859-7936)
- Johanna M.A. Pijnenborg
- Marc P.L.M. Snijders (ORCID: https://orcid.org/0000-0002-2434-7442)
- Marike Lombaers (ORCID: https://orcid.org/0000-0002-7384-2570)
- Arjen Hommersom (ORCID: https://orcid.org/0000-0003-0125-1680)
- Petra Bretová (ORCID: https://orcid.org/0000-0003-1082-433X)
- Marcel Grube (ORCID: https://orcid.org/0000-0002-6609-8827)
- Xavier Matías‐Guiu (ORCID: https://orcid.org/0000-0002-7201-6605)
- Peter Bronsert (ORCID: https://orcid.org/0000-0001-8558-0347)
- Jasmin Asberger (ORCID: https://orcid.org/0000-0003-2226-769X)
- Hege F. Berg (ORCID: https://orcid.org/0000-0002-1712-6609)
- Martin Koskas (ORCID: https://orcid.org/0000-0003-3872-2810)
- Casper Reijnen (ORCID: https://orcid.org/0000-0001-6873-7832)
- Eva Colás (ORCID: https://orcid.org/0000-0003-0302-4828)
- Jutta Huvila
- Irene de la Calle (ORCID: https://orcid.org/0000-0002-2227-1640)
- Louis J.M. van der Putten
- Stefan Kommoss
- Ally Sprik
Institutions
- Hebron University (PS)
- Universitat Autònoma de Barcelona (ES)
- Radboud University Nijmegen (NL)
- Universitat de Lleida (ES)
- University of Freiburg (DE)
- Masaryk University (CZ)
- Haukeland University Hospital (NO)
- University Medical Center Freiburg (DE)
- Turku University Hospital (FI)
- Hospital Universitari Arnau de Vilanova (ES)
- Radboud University Medical Center (NL)
- University Hospital Brno (CZ)
- Vall d'Hebron Institut de Recerca (ES)
- Eurofins (Netherlands) (NL)
- Radboud Institute for Molecular Life Sciences (NL)
- Canisius-Wilhelmina Ziekenhuis (NL)
- Hospital Del Mar (ES)
- Instituto de Investigación Biomédica de Lleida (ES)
- Hôpital Bichat-Claude-Bernard (FR)
- University Hospital in Halle (DE)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Jeroen Bosch Ziekenhuis (NL)
- University of Bergen (NO)
- Open University of the Netherlands (NL)
- University of Twente (NL)
- KU Leuven (BE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-10-19
- DOI
- https://doi.org/10.1016/j.ejca.2025.116058
- Citations
- 2
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.11
Funders
- Pfizer
- AstraZeneca
- Fundació la Marató de TV3
- Novocure
- Clovis Oncology
- Accuray
- Incyte
- Seagen
- Radboud Universiteit
- Eisai
- KU Leuven
- Haukeland Universitetssjukehus
- PharmaMar
- Samsung
- Instituto de Salud Carlos III